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In 1956 Gansler (1) observed infiltration of the rat uterus by eosinophils
coincident with the estrus cycle . This observation was confirmed and extended
by the work of Bassett (2) and Ross and Klebanoff (3) . Since then, various
investigations have shown (a) that injection of estrogen into castrated or imma-
ture rodents leads to immediate uterine eosinophilia (4-10), (b) that the uterine
eosinophil is marrow derived (11), (c) that the uterine eosinophil number varies
>100-fold during the normal estrus cycle (12), (d) that uterine content of
eosinophil peroxidase varies directly with the estrus cycle (13, 14), (e) that
eosinophils possess a unique cell surface estrogen receptor (4-9), and (f) that
estrogen-induced uterine eosinophilia apparently has no dependence upon uter-
ine mast cell activity (15-18) .
In contrast, there are few observations relating eosinophils to human repro-
ductive physiology . Cyclic eosinopenia correlating with ovulation has been re-
ported (19-21) and cyclic variations in endometrial eosinophils and their uptake
of tritiated estradiol have also been observed (22) . However, no role for the
eosinophil in normal human reproduction is presently recognized . During the
course of studies of hypersensitivity diseases in pregnancy we found that serum
levels of a molecule immunochemically similar to the eosinophil granule major
basic protein (MBP)' were elevated in all pregnant women, increasing during
pregnancy and decreasing to normal levels after parturition . Becauseeosinophilia
is not a feature of normal pregnancy, and serum levels of other eosinophil
proteins are not elevated, the results of this study suggest that the immunoreac-
tive MBP in pregnancy serum is derived from a source other than the eosinophil .
Materials and Methods
Dithiothreitol, iodoacetamide, equine liver catalase, sodium borate, boric acid, Staphy-
lococcus aureus protein A, chloramine T, protamine sulfate, bovine serum albumin, Trizma
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immunoradiometric assay .
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base, and sucrose were purchased from Sigma Chemical Co., St. Louis, MO. Purified
human chorionic gonadotrophin and purified beta subunit of human chorionic gonado-
trophin were gifts from Dr. R. Ryan, Mayo Clinic. Purified, radiolabeled human prolactin
was a gift from Dr. N. Jiang, Mayo Clinic. Sephadex G-50 and Sepharose 6B-CL were
from Pharmacia Fine Chemicals, Piscataway, NJ. Iodine-131 and iodine-125 (carrier free)
were protein iodination grade from New England Nuclear, Boston, MA. Microelisa 96-
well flexible plastic plates were from Dynatech Laboratories, Inc., Alexandria, VA.
Gamma counting was performed on either a Nuclear Chicago gamma spectrometer or a
gamma counter (Tracor Analytic Inc ., Elk Grove Village, IL). Data were analyzed on a
model 9845B computer (Hewlett-Packard Co., Palo Alto, CA).
Double Antibody Inhibition Radioimnzunoassay (DARIA).for MBP, Eosinophil Cationic Protein
(ECP), Eosiraophil-derived Veurotoxin (EDN), and Charcot-Leyden Crystal Protein (CLC).
DARIA for MBP and CLC have been described (23-25). ECP and EDN were assayed by
the same method. Briefly, human ECP and CLC (lysophospholipase [26]) were isolated
and purified as described elsewhere (25),2 and rabbit antisera to the individual proteins
were prepared. Proteins were radiolabeled with ` s 'I by the chloramine T method (27),
and in preliminary experiments the dilution of antiserum required to bind 50% of
radiolabeled protein was determined. The assay was performed as follows: (a) assay buffer
(0 .1 M Na2HP04-KH2PO4, pH 7 .4, made 1 mg/ml in protamine sulfate and 0.5% vol/
vol in either fetal calf or newborn calf serum [PPF buffer]), 500 Al, was added to 100 pl
of test sample and 100 pl of the appropriate dilution (1 :1,000-1 :10,000) of rabbit
antiserum ; (b) after incubations of 30 min at 37 ° C and 15 min at 4°C, 1 ng of "'I-labeled
MBP, ECP, EDN, or CLC in 100 pl PPF buffer was added, and the tubes were incubated
overnight at 4°C; and (c) immune complexes were precipitated by the addition of 100 ,.l
of a 1 :20 dilution of normal rabbit serum, followed by 200 kl of neat burro anti-rabbit
IgG antiserum. After 3 h of incubation at 4°C, precipitation was complete and the tubes
were centrifuged for 20 min at 2,500g. The supernatants were decanted and radioactivity
in the precipitates was counted. Controls included tubes to determine total counts added
and tubes in which specific antibody was omitted to determine nonspecific trapping of
counts. Normal serum and serum from a patient with the hypereosinophilic syndrome
were included in all assays as internal standards. Radioimmunoassay data were analyzed
using a radioimmunoassay program (HP No. 9845-14254) from Hewlett-Packard Co. In
those instances where human serum was tested in the guinea pig MBP DARIA (23),
performance of the assay was exactly the same as described above.
Two-Site Immunoradionietric Assay for MBP.
￿
In the two-site immunoradiometric assay
(TSIRA) (28), specific rabbit IgG antibody was bound to a plastic surface and incubated
with MBP-containing solutions; bound MBP was detected by radiolabeled affinity-purified
antibody to MBP. The IgG fraction of anti-MBP antiserum for coating plates was prepared
by equilibrating rabbit anti-human MBP serum with pH 7 .8, 0.1 M phosphate buffer on
a Sephadex G-25 column. Void volume fractions were pooled and applied to a staphylo-
coccus protein A-Sepharose 4B column . After washing, bound IgG was rapidly eluted
with 0.58% acetic acid into tubes containing pH 8.4, 0.4 M Na2HB04-NaH2BO4 buffer.
Elution was monitored by absorbance at 277 nm, and fractions with peak absorbance
were pooled and diluted with 0.002 M, pH 8.2 phosphate buffer.
Microelisa flexible plastic plates (well volume, 0.3 ml) were coated with 100 Al per well
of anti-MBP IgG, 3.2 mg/ml, in pH 8.2, 0 .001 M phosphate buffer (coating buffer) by
overnight incubation at 4°C. Remaining protein-binding sites on the plastic were blocked
by incubation with coating buffer made 10 mg/ml in bovine serum albumin, 200 U1 per
well, for 6 h at room temperature. Wells were aspirated, washed with coating buffer, and
stored at 4'C.
The second stage of the assay used anti-human MBP antibody purified by affinity
chromatography. Reduced and alkylated MBP (3.8 mg) was coupled to cyanogen bromide-
activated Sepharose 6B-CL (8 ml swollen gel) as described (29), and a column was poured.
2 Ackerman, S. J., D. A. Loegering, P. Venge, I . Olsson, J. B. Harley, A. S. Fauci, G. J. Gleich.
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Immune rabbit serum (25 ml) was applied to the column, the solid phase was washed with
citrate-phosphate buffer, pH 7.4, and bound protein was eluted with a linear gradient
using a pH 2.2 citrate-phosphate limit buffer. Fractions were collected into 0 .2 M, pH
8.4 phosphate buffer for immediate neutralization. Elution was monitored by absorbance
at 277 nm, and tubes from the final absorbance peak at pH 2.8 were pooled and shown
to possess anti-MBP activity in a modified DARIA. The affinity-purified antibody to MBP
was radioiodinated by the iodine monochloride method of Bale et al. (30) as modified for
microtechnique (31), and specific activities of 12-15 mCi/mg protein were typically
obtained.
The assay was performed by adding 100 u1 of purified reduced and alkylated MBP,
diluted serially in PPF buffer, to antibody-coated wells for a standard binding curve.
Reduced and alkylated samples, 100 jl, were dispensed into wells for analysis. Nonspecific
binding was measured in wells receiving only PPF buffer. Plates were incubated overnight
at 4°C in a humidified chamber and wells were aspirated and washed thrice with coating
buffer. Radiolabeled affinity-purified antibody, diluted in PPF buffer to ^-20,000 cpm/
100 ul, was added to each well. Plates were incubated for 4-6 h at room temperature;
the wells were aspirated, washed 10 times with coating buffer made 1 % in Tween 20,
dried, and cut out for gamma counting. All samples were assayed in duplicate, and before
data analysis, counts in control wells containing only PPF were subtracted.
Reduction and Alkylation of Serum.
￿
Measurement of maximal MBP levels in serum
requires reduction and alkylation before assay (24). Therefore, before MBP measurement
by the DARIA or the TSIRA, sera were reduced and alkylated unless otherwise specified.
50,u] of serum was diluted with 130 1l 0.1 M Tris-hydroxymethylaminomethane, 0 .12 M
NaCl, 0.01 M EDTA pH 8.2 buffer; dithiothreitol solution (0.075 M) was added to a final
concentration of 0.0075 M. After60 min incubation at room temperature, alkylation was
accomplished by the addition of sufficient 0 .15 M iodoacetamide to achieve a final
concentration of 0.015 M. Samples were incubated for 20 min at room temperature and
assayed immediately.
Gel Filtration of Sera.
￿
A 1 .6 X 50-cm column of Sephadex G-50 fine was poured and
equilibrated with acid-saline (0.01 M HCl, 0.15 M NaCl, pH 2). Before chromatography,
serum or clotted plasma was reduced, alkylated (see above), and acidified to pH 2 by
dropwise addition of 2 M HCl with vigorous mixing. Acidification resulted in the
formation of precipitate, and samples were clarified by centrifugation at 40,000 g for 40
min before application to the column . Samples were made 5-10% in sucrose and applied
under the eluent to the column . The column was eluted with acid saline, at 5 ml
cm-'hr-' at VC, C, and 2.7-ml fractions were collected. Elution was monitored by absorbance
at 277 nm. After neutralization in PPF buffer, a sample of each fraction was assayed for
MBP in the TSIRA.
Clinical Specimens.
￿
413 serum samples from 397 pregnant women in various stages of
gestation were available from a previous unrelated study. Cord serum and amniotic fluid
were available from the obstetrical unit at the Rochester Methodist Hospital, Rochester,
MN. Paired serum samples were obtained from six women at delivery and at 6 wk
postpartum . One woman volunteered serum samples at monthly intervals throughout
gestation, and after a second gestation, specimens were obtained every other day for 6
wk postpartum .
Statistical Analyses.
￿
Statistical analyses were performed using the regression analysis
(HP 09845-15031), analysis of covariance (HP 09845-15171), general statistics (HP
09845-15011), and statistical graphics (HP 09845-15021) programs from Hewlett-Packard
Co.
Results
MBPLevels in Pregnancy and Cord Sera.
￿
Table I shows MBP levels in sera from
pregnant women, paired cord sera, and control sera. MBP levels in the pregnancy
sera were >15-fold above normal levels, similar to values found in patients with
the hypereosinophilic syndrome. In contrast, cord serum contained normal levels1214 GESTATIONAL IMMUNOREACTIVE EOSINOPHIL MAJOR BASIC PROTEIN
* Thematernal sera were obtained during labor.
$ Normal serum included as internal standard. MBP levels in 105 normal
blood bank donor sera had a mean of 454 ng/ml and a range of 312-
800. 95% of values were <600 ng/ml(24).
TABLE I
Measurement of Serum MBP by DARIA
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FIGURE 1 .
￿
Comparison of dose-response curves for pregnancy sera (*, ", ") and purified
MBP (p) in the DARIA. (A) Untransformed data, (B) the same data after logit-log transfor-
mation. Linear regression analysis showed r2 = 0.98 for purified MBP and a mean r2 of 0.97
(range 0.96-0.99) for the pregnancy sera. One-way analysis of covariance indicated that the
slopes for titrations of pregnancy sera differ from that of pure MBP (Fa,15 = 5.86, P < 0.01).
of MBP. Amniotic fluid obtained from one patient during the first stage of labor
contained 971 ng/ml of MBP.
Specinty of the ImmunochemicaI Detection ofMBP.
￿
To determine whether MBP
in pregnancy sera was immunochemically similar to purified MBP, we titrated
three such sera in the DARIA. Fig. 1 shows that the slopes of the regression lines
for the pregnancy sera and MBP standard were quite similar, though not
identical, and the pregnancy sera completely inhibited the binding of 1311-MBP
Condition Patient Sample source MBP
nglml
Pregnancy 1 Maternal* 12,671
Cord 468
2 Maternal 10,721
Cord 428
3 Maternal 12,160
Cord 488
4 Maternal 11,521
Cord 610
5 Maternal 8,818
Cord 494
Hypereosinophilic syndrome 1 13,600
2 14,400
3 7,200
4 8,172
Normal* 415MADDOX ET AL.
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to antibody. Table II shows that pregnancy sera required reduction and alkyla-
tion to demonstrate maximal MBP immunoreactivity, as is the case for MBP in
sera of patients with eosinophilia. Previous experiments have shown that only
I % of MBP added to serum is recovered in the DARIA if the serum is not
reduced and alkylated before assay (24). Table II also shows that the heat lability
of MBPin pregnancy serum depended upon antecedent reduction andalkylation,
as is the case for MBP in sera of patients with eosinophilia. Heatingof pregnancy
serum without. prior reduction and alkylation did not alter immunoreactivity, in
keeping with prior findings (24).
A number of pregnancy-associated serum proteins have been described (32-
34), and we investigated whether an acidic pregnancy-associated protein might
compete for thebasicradiolabeled MBP in the inhibition assay. This would result
in inhibition in the DARIA and lead to a spurious MBP elevation. We tested this
in two ways: (a) by assaying pregnancy sera in the guinea pig MBP DARIA, and
(b) by developing a TSIRA that detects MBP by direct multivalent ligand binding
rather than inhibition. Although human and guinea pig MBP are quite similar
in their physicochemical properties, our antisera to these proteins do not appre-
ciably cross-react (24). If a hypothetical acidic pregnancy-associated protein were
competing for labeled MBP on the basis of charge, then the species of origin of
the radiolabeled MBP should have no influence, and an analysis of pregnancy
sera in the guinea pig MBP assay should show elevated levels of guinea pig MBP.
Table III shows that pregnancy sera failed to show any inhibition in the guinea
pig assay. In the case of the TSIRA, the hypothetical acidic pregnancy-associated
TABLE II
Effect of Reduction, Alkylation, and Heating on MBP in Pregnancy Sera*
* Test substances were reduced andalkylated as describedin Methods andanalyzed by
the DARIA.
Test specimen Treatment MBP
nglinl
Pregnancy serum 1 None 51
Reduced& alkylated 5,914
Pregnancy serum 2 None 36
Reduced& alkylated 4,805
Pregnancy serum 3 Reduced & alkylated 5,425
Reduced & alkylated, then heated at 1,945
56°C for 3 h
Heated at 56°C for 3 h, then reduced 5,431
& alkylated
Hypereosinophilic syndrome Reduced & alkylated 5,592
serum Reduced & alkylated, then heated at 1,313
56°C for3 h
Heated at 56°C for 3 h, then reduced 6,982
& alkylated
MBP (500 ng) None 500
Heated at 56°C for 3 h 01216 GESTATIONAL IMMUNOREACTIVE EOSINOPHIL MAJOR BASIC PROTEIN
TABLE III
Detection ofMBPin Pregnancy Sera by DARIAforHuman and
Guinea Pig MBP
TABLE IV
Measurement ofMBP in Pregnancy andNormal Sera by the TSIRA
* Mean level, 4,331 ng/ml ± 200 (1 SD).
$ Assay of 40 normal blood bank donorsera (20 males, 20 females) by the
TSIRAgave a mean level of 449 ± 177 (1 SD); there was no statistically
significant difference between levels in normal males and normal fe-
males.
protein would diminish serum MBP. As shown in Table IV, pregnancy sera
showed elevated levels of MBP in the TSIRA. Fig. 2 shows that the slopes ofthe
dose-response curves for normal, hypereosinophilic, and pregnancy sera in the
TSIRA were the same and did not differ from purified MBP. The maximal
binding obtained with pregnancy serum was also similar to that obtained using
serum from a patient with the hypereosinophilic syndrome.
Prior studies found a correlation between the serum levels of MBP and
peripheral blood eosinophilia (35, 36) . Therefore, we obtained simultaneous
Serum Patient Week of
gestation Human MBP
nglml
Guinea
pig MBP
Pregnancy 1 10 2,794 7
2 13 2,350 11
3 15 3,454 7
4 11 2,303 12
Hypereosinophilic 1 13,600 9
syndrome 2 14,400 11
3 7,200 13
4 8,172 33
Serum Patient MBP
nglml
Pregnancy* 1 4,268
2 4,487
3 4,297
4 4,242
5 4,428
6 4,063
7 4,643
8 4,429
9 4,512
10 4,122
11 4,457
12 4,424
13 3,937
Hypereosino- 8,040
philic syndrome
Normal* 412MADDOX ET AL.
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FIGURE 2. Comparison of dose-response curves for pregnancy serum and MBP in the
TSIRA. Pregnancy serum (p), hypereosinophilic syndrome serum (p), normal serum (A),
purified MBP (/) and blood bank normal donor serum (9). (A) Untransformed data, (B) the
same data after log-log transformation. Linear regression analysis showed r2 = > 0.97 for all
curves. One-way analysis of covariance indicated that slopes of all regressions do not differ
(F4,a, = 1.31; not significant).
TABLE V
Correlation ofMBP Levels and Blood Eosinophil Counts*
* There was no correlation between MBP levels and eosinophil counts (r
= 0.15, F,,7 = 0.164; notsignificant).
$ Pregnancy plasma was analyzed in the DARIA.
§Based on an automated 10,000 cell differential count.
121 7
plasma MBP levels and peripheral blood eosinophil counts from nine women,
three in each trimester of pregnancy. However, as shown in Table V, there was
no correlation between MBP levels and eosinophil counts. Prior studies also
found a positive correlation between serum levels of MBP and CLC protein
(lysophospholipase) (35, 36). Therefore, we determined whether the levels of
CLC and two other eosinophil-associated proteins, ECP and EDN (37-39), were
elevated in pregnancy serum. Table VI showsthat CLC levels were not elevated,
and that the levels of ECP and EDN in the pregnancy sera were depressed
compared with normal sera (P < 0.001 in both cases). In contrast, all four of the
eosinophil proteins were elevated in the serum ofa patient with the hypereosin-
ophilic syndrome.
Finally, we found no inhibition by human chorionic gonadotrophin or its beta
Gravid patient MBP* Week of gesta-
tion
Eosinophils
microliter
~er
ngl>nl
1 872 10 116
2 1,028 10 15
3 1,375 12 64
4 1,271 13 41
5 3,401 17 163
6 5,127 23 42
7 9,002 33 31
8 10,655 33 63
9 6,850 35 1501218 GESTATIONAL IMMUNOREACTIVE EOSINOPHIL MAJOR BASIC PROTEIN
TABLE VI
Measurement ofEosinophil-associated Proteins in PregnancySera by DARIA*
* Values are reported as z ± I SD.
$ A group of 20 consecutive pregnancy sera were selected from the larger group of 413 (see Fig. 3)
forassays of MBP, ECP, andEDN. The CLC assays were performed on 12 otherarbitrarily chosen
sera from the group of 413.
§Normal values for MBP and CLC are thosepreviously published (24, 25); values for ECPand EDN
are for 20 normal female blood bank donors.
Levels reported here for ECP in normal sera are quite similar to those reported by Venge et al.
(40): mean, 31 ng/ml; range5-55 ng/ml.
subunit in the DARIA, or binding activity in the TSIRA. Also, purified MBP
and serum from a patient with the hypereosinophilic syndrome failed to show
activity in a radioimmunoassay forhuman chorionicgonadotrophin (41). Purified
radiolabeled prolactin was not bound by anti-MBP antibody.
Changes in MBP Levels During and After Pregnancy.
￿
The above results estab-
lished that MBP was elevated in sera of pregnant women. We next determined
the relationship between the elevation of MBP and the time of gestation. Fig. 3
shows the MBP levels in 413 sera according to the week of gestation; MBP was
elevated (>600 ng/ml) in all sera . MBP levels were elevated early in gestation,
peaked rapidly to about a 10-fold elevation above normal by the end of the first
trimester, and remained relatively close to that level for the remainder of
gestation. Analysis of the relationship between MBP level and time showed a
significant positive correlation (r2 = 0.64, F = 86 .9, P < 0.001).
In one pregnant woman, MBP was measured in serial samples obtained
throughout gestation. Fig. 4 shows that MBP levels were elevated by week 12
(when the diagnosis of pregnancy was first made) and remained between 6,000
and 8,000 ng/ml until after week 34, when they increased to a maximum of
almost 14,000 ng/ml. When the MBP levels from the patients in Fig. 3 were
examined for a similar near-term rise, a suggestive trend was observed; however,
mean MBP levels at 37 and 41 wk were not statistically different.
To determine the change in MBP levels after pregnancy, we analyzed serum
samples from six women on the day of delivery and at 6 wk postpartum in the
DARIA. Levels fell from a mean of 11,732 ± 2215 ng/ml (1 SD) on the day of
delivery to a mean of 761 ± 150 ng/ml (1 SD) by the 6th wk. Fig. 5 shows serum
MBP levels after parturition in one patient. The level dropped sharply in the 2
wk after delivery, with a calculated half-time of 13 .7 d.
Behavior of MBP in Pregnancy Sera on Gel Filtration.
￿
Previous work demon-
strated that gel permeation chromatography of serum that has been reduced,
MBP CLC ECP EDN
ng/ml
Pregnancy$ 4,271 ± 2,411 45 ± 19 9 ± 5 20 ± 11
(Range) (1,344-8,036) (23-80) (3-21) (8-49)
Hypereosino- 7,814 7,420 411 8,916
philic syndrome
Normal blood donors§ 454 ± 90 41 ± 37 18 ± 91 74 ± 53
(Range) (312-800) (8-199) (5-40) (17-191)FIGURE 3 .
￿
Time-related changes of serum MBP during gestation . Arithmetic mean values
forMBP levels were analyzed by the DARIA in 413serum samplesfrom 397womenaccording
to the week of gestation . Data from weeks 32 and 33 are pooled . The horizontal shading
across the bottom indicates the 5th to 95th percentiles for MBP levels in normal subjects, and
the verticle error bars denote I SD . No samples before the 5th wk of gestation were available
for analysis . The numbers of samples analyzed in each week are given at the top of the graph .
Week of gestation was determined by back-calculation from the date of delivery, taking into
account the pediatrician's estimate of the gestational age of the delivered infant . Polynomial
regression on all the data together with residual analysis identified cases in which MBP levels
were >2 SD from the equation for the line ; medical records for all cases were reviewed, and
no relationship was found betweenextreme levels of MBPand complications of gestation .
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Serial determinations of serum MBP in a gravida 1, para 0 pregnant woman by
the DARIA . The first data point represents aserumspecimen before conception. The shaded
area at the bottom of the plot represents the 5th to 95th percentiles for MBP levels in the
normal population .
alkylated, and acidified results in the resolution of MBP at an elution volume
correspondingto the molecular weight (9,300) ofmonomerMBP (24) .We tested
the ability of Sephadex G-50 gel chromatography to resolve such an MBP peak
from pregnancy sera . Fig . 6 shows that under conditions in which serum MBP
from a patient with hypereosinophilic syndrome eluted at the expected volume
for monomeric MBP, the MBP in pregnancy serum eluted at the void volume of1220 GESTATIONAL IMMUNOREACTIVE EOSINOPHIL MAJOR BASIC PROTEIN
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FIGURE 5.
￿
Postpartum changes in gestational MBP levels. Data are from sera of a single
subject tested in the DARIA. (A) Level vs. time, (B) linear regression of log-transformed levels
vs. time. For this regression, r = -0.98; the line is described by the equation y = 0.22 x +
3.65. T1/ 2 for MBP was 13.7 d.
the column. Six separate experiments, using six different pregnancy sera, gave
identical results.
Discussion
The ultrastructural localization of eosinophil granule MBP within the eosino-
phil, its physicochemical properties, and its biological activities have been re-
viewed elsewhere (42, 43). Briefly, human MBP is alow molecular weight (9,300),
extremely basic polypeptide (isoelectric point >10) that, in the guinea pig, forms
the electron-dense crystalloid core of the eosinophil-specific granule. It contains
at least two sulfhydryl groups and it readily self-associates through disulfide
linkages to form polymeric molecules. In biological fluids, such as serum and
sputum, MBP is protein bound, and these fluids must be reduced and alkylated
to demonstrate maximal immunoreactivity. MBP is elevated in thesera ofpatients
with eosinophilia and in the sputum of patients with asthma. MBP is toxic to
several helminths, normal mammalian cells, and tracheal epithelium. Further,
immunofluorescence examinations of parasites in tissues reveal large quantities
of MBP localized around and on the surface of the parasites (44). Similar
examinations on lung tissues from asthmatic patients reveal MBP as a prominent
component of the mucus plugs that obstruct airways (45). MBP has therefore
been postulated as a mediator of eosinophil killing of parasites and of the
respiratory epithelial damage observed in bronchial asthma. Accordingly, the
finding ofelevated serum levels of an immunoreactive form ofthis toxic molecule
during pregnancy was unanticipated.
We found elevations in serum MBP during human gestation, with levels
correlated with the stage of gestation. At the earliest time measured (5 wk),
levels were already elevated more than threefold above the upper normal limit
(600 ng/ml). As gestation progressed, levels increased until a plateau of 7,500
ng/ml was reached at about the 20th wk of pregnancy. The immunochemical
specificity of serum MBP elevation was tested in several ways. In the DARIA,
pregnancy serum could fully displace radiolabeled MBP from specific antibody.
In the TSIRA, pregnancy serum displayed maximal binding comparable to that0
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FIGURE 6.
￿
Gel-permeation chromatography of pregnancy serum MBP. A single column of
Sephadex G-50 fine gel equilibrated with 0.15 M NaCI/0.01 M HCl was used. The arrow
marked "v" denotes column void volume andthe otherarrow indicates the elution volume for
pure radiolabeled MBP. (A) Elution profile when reduced and alkylated, acidified pregnancy
serum was chromatographed, and resultant fractions were neutralized and assayed for MBP
by the TSIRA. Under these conditions, recovery of MBP (based on that in the initial serum
sample) wasquantitative. (B)Elution profile forpregnancy serum prepared as in A except with
4 ug of purified reduced andalkylatedMBPadded;fractions were analyzed as in A. (C)Elution
profile for serum (treated as in A) from a male with the hypereosinophilic syndrome.
obtained with serum from patients with hypereosinophilic syndrome, and the
slopes of pregnancy serum and pure MBP standard dose-response curves were
identical. Further, the same pattern of heat lability and an absolute requirement
for reduction and alkylation before immunochemical detection was shown for
the molecule in pregnancy sera, in keeping with prior results for MBP in serum
from patients with eosinophilia (24). We showed that nonspecific factors in1222 GESTATIONAL IMMUNOREACTIVE EOSINOPHIL MAJOR BASIC PROTEIN
pregnancy serum were not responsible for results obtained in the DARIA,
because pregnancyserum did not inhibit detection of guinea pig MBP. We tested
for the possibility of cross-reaction among two pregnancy-associated proteins,
human chorionic gonadotrophin and prolactin, and MBP, and have found no
evidence of such cross-reactivity.
In spite of these lines of evidence supporting the immunochemical identity
between the MBP detected in pregnancy sera and the MBP from the eosinophil
granule, four anomalous findings have emerged. First, we found no correlation
between numbers ofeosinophils in peripheral blood and MBP levels in pregnancy
serum. Second, measurement of three other eosinophil-associated proteins in
pregnancy serum yielded normal or subnormal values, in contrast to the marked
elevations of these proteins in serum of patients with eosinophilia. Third, al-
though very similar, the slopes of dose-response curves for pregnancy sera and
MBP standard in the DARIA were not identical. Fourth, gel permeation chro-
matography ofpregnancy serum resulted in theelution of MBP immunoreactivity
at the void volume of a Sephadex G-50 column, indicating a molecular size
greater than 30,000. These findings suggest that the MBP molecule in preg-
nancy serum differs from that in the eosinophil granule, and suggests the
possibility of a non-eosinophil source for the MBP molecule in pregnancy. For
these reasons we have referred to the MBP in pregnancy serum as immunoreac-
tive MBP to indicate that it likely differs from the MBP derived from the
eosinophil granule.
The data presented here show that immunoreactive MBP levels in pregnancy
increase in a manner similar to the increase in placental size during gestation
and decrease following delivery of the placenta. Furthermore, MBP levels in
cord sera and amniotic fluid were a great deal lower than in maternal serum.
Most of the known pregnancy-associated proteins are produced by the placenta
(32-34) so it seemed reasonable to investigate this tissue as a source of the
molecule in pregnancy serum. We have recently demonstrated immunoreactive
MBP in the human placenta, both by immunofluorescence (46) and chemical
extraction .' These findings suggest that the MBP detected in human gestation is
of placental origin . If so, considerable sequence homology must exist between
the eosinophil granule protein and the placental protein because of the remark-
able immunochemical similarity between the two. There is ample precedent for
multiple tissue sources of various proteins that, through gene conservation,
demonstrate major sequence homology with one another (47, 48). However, in
most of these instances, a shared function is demonstrable as well. At present,
there is no obvious explanation for the placental elaboration of a molecule whose
counterpart in the eosinophil appears to function as a helminthotoxin or cyto-
toxin.
Summary
We have shown that serum levels of a molecule immunochemically similar to
eosinophil granule major basic protein (MBP) are elevated in pregnant women
throughout gestation. MBP levels increase during gestation and plateau at
s Maddox, D. E., G. M. Kephart, J. H. Butterfield, C. B. Coulam, K. Benirschke, and G. J. 6leich.
Localization of eosinophil major basic protein in human placenta. Manuscript in preparation.MADDOX ET AL.
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^-7,500 ng/ml by the 20th wk (>10-fold above normal). Levels return to normal
after delivery, with a T'/2 of 13.7 d. The MBP in pregnancy serum is remarkably
similar to the eosinophil granule MBP in that: (a) pregnancy MBP fully inhibits
the binding of radiolabeled MBP standard in a double antibody radioimmunoas-
say ; (b) this inhibition reaction is specific for human MBP because pregnancy
serum produces no inhibition of the binding of radiolabeled guinea pig MBP in
the guinea pig MBP radioimmunoassay; (c) in a two-site immunoradiometric
assay for MBP, slopes of dose-response curves for pregnancy serum, purified
MBP, and serum from a patient with hypereosinophilic syndrome are identical,
and maximal binding is comparable; (d) reduction and alkylation of pregnancy
sera increases measured MBP 100-fold, as previously shown for eosinophil
granule MBP in serum; and (e) the MBP in pregnancy serum demonstrates the
same pattern of heat lability as has been previously reported for MBP.
Four observations have raised the possibility that the eosinophil is not the
source of the MBP in pregnancy serum: (a) no correlation between serum MBP
level and peripheral blood eosinophil count exists in pregnant women, in contrast
to previous studies of patients with eosinophilia; (b) levels of three other eosino-
phil-associated proteins are normal or low in pregnancy sera, whereas the serum
levels of these proteins are elevated in patients with eosinophilia; (c) the slopes
of dose-response curves for pregnancy sera and MBP standards differ in the
double antibody radioimmunoassay; and (d) the molecule in pregnancy serum
elutes from Sephadex G-50 columns at the void volume, while eosinophil granule
MBP and the MBP in serum of patients with eosinophilia elute at a volume
consistent with the previously established molecular weight of 9,300. These
findings suggest that the MBP in pregnancy serum is derived from a source
other than the eosinophil.
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